Changes in the profile and therapeutic care of people who use drugs with HCV mono-infection: a retrospective study between 2015 and 2019 from a monocentric tertiary referent center in France.

Date publication

mai 2022

Journal

European journal of gastroenterology & hepatology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas , Dr HABERSETZER François , Pr MEYER Nicolas

Tous les auteurs :
Doffoel M, Tripon S, Ernwein F, Chaffraix F, Haumesser L, Bader R, Lang JP, Lang A, Paya D, Royant M, Velay-Rusch A, Tebacher M, Meyer N, Habersetzer F, Baumert T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35421021

Résumé

People who use drugs (PWUDs) are the main group at risk for hepatitis C virus (HCV) transmission and a key population for hepatitis C elimination. Multidisciplinary team (MDT) meetings were set up in France in December 2014 within regional reference centers to supervise the prescriptions and delivery of direct-acting antivirals (DAAs) to optimize the management of HCV infection. The aim of this retrospective study was to analyze the changes in the profile and therapeutic care of PWUDs with HCV mono-infection according to the evolution of MDT meetings in a regional tertiary reference center.

Référence

Eur J Gastroenterol Hepatol. 2022 May 1;34(5):560-566